Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer

Alekseenko, I.V.; Snezhkov, E.V.; Chernov, I.P.; Pleshkan, V.V.; Potapov, V.K.; Sass, A.V.; Monastyrskaya, G.S.; Kopantzev, E.P.; Vinogradova, T.V.; Khramtsov, Y.V.; Ulasov, A.V.; Rosenkranz, A.A.; Sobolev, A.S.; Bezborodova, O.A.; Plyutinskaya, A.D.; Nemtsova, E.R.; Yakubovskaya, R.I.; Sverdlov, E.D.

Авторы: Alekseenko Irina V., Snezhkov Eugene V., Chernov Igor P., Pleshkan Victor V., Potapov Victor K., Sass Alexander V., Monastyrskaya Galina S., Kopantzev Eugene P., Vinogradova Tatyana V., Khramtsov Yuri V., Ulasov Alexey V., Rosenkranz Andrey A., Sobolev Alexander S., Bezborodova Olga A., Plyutinskaya Anna D., Nemtsova Elena R., Yakubovskaya Raisa I., Sverdlov Eugene D.
Журнал: Journal of Translational Medicine
Том: 13
Номер: 78
Год издания: 2015
Издательство: BioMed Central
Местоположение издательства: London
Первая страница: 1
Последняя страница: 16
DOI: 10.1186/s12967-015-0433-0
Аннотация: Background Gene-directed enzyme prodrug therapy (GDEPT) represents a technology to improve drug selectivity for cancer cells. It consists of delivery into tumor cells of a suicide gene responsible for in situ conversion of a prodrug into cytotoxic metabolites. Major limitations of GDEPT that hinder its clinical application include inefficient delivery into cancer cells and poor prodrug activation by suicide enzymes. We tried to overcome these constraints through a combination of suicide gene therapy with immunomodulating therapy. Viral vectors dominate in present-day GDEPT clinical trials due to efficient transfection and production of therapeutic genes. However, safety concerns associated with severe immune and inflammatory responses as well as high cost of the production of therapeutic viruses can limit therapeutic use of virus-based therapeutics. We tried to overcome this problem by using a simple nonviral delivery system. Methods We studied the antitumor efficacy of a PEI (polyethylenimine)-PEG (polyethylene glycol) copolymer carrying the HSVtk gene combined in one vector with granulocyte–macrophage colony-stimulating factor (GM-CSF) cDNA. The system HSVtk-GM-CSF/PEI-PEG was tested in vitro in various mouse and human cell lines, ex vivo and in vivo using mouse models. Results We showed that the HSVtk-GM-CSF/PEI-PEG system effectively inhibited the growth of transplanted human and mouse tumors, suppressed metastasis and increased animal lifespan. Conclusions We demonstrated that appreciable tumor shrinkage and metastasis inhibition could be achieved with a simple and low toxic chemical carrier – a PEI-PEG copolymer. Our data indicate that combined suicide and cytokine gene therapy may provide a powerful approach for the treatment of solid tumors and their metastases.
Добавил в систему: Соболев Александр Сергеевич

	ИСТИНА	Войти в систему Регистрация
	Интеллектуальная Система Тематического Исследования НАукометрических данных
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

Интеллектуальная Система Тематического Исследования НАукометрических данных

Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymerстатья